Compare Cassava Sciences Inc (FLNA) vs iShares Core High Dividend ETF (HDV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs iShares Core High Dividend ETF — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while iShares Core High Dividend ETF trades at $29.07. The key difference: iShares Core High Dividend ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | HDV | |
|---|---|---|
Market Cap | $47.75M | — |
Sector | Health | — |
52-Week High | $4.64 | $29.14 |
52-Week Low | $0.87 | $23.64 |
Enterprise Value | -$34.93M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
HDV trades at $28.78, up 0.21% with a bullish technical signal. It yields approximately 3.1% from dividends, with recent payouts in June and July 2026. The ETF focuses on high-quality U.S. large-cap dividend stocks, outperforming the S&P 500 year-to-date by 9 percentage points. News highlights its appeal for retirement income and institutional buying, such as 180 Wealth Advisors increasing its stake by 386.2% in Q2 2026.
The outlook is positive due to strong dividend sustainability and defensive sector weighting, but risks include interest rate sensitivity and concentrated holdings. Analysts favor HDV for income-focused portfolios, citing its quality screening and lower volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →
